| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Simone Esposito, Laura Orsatti, Vincenzo Pucc. Subcutaneous Catabolism of Peptide Therapeutics: Bioanalytical Approaches and ADME Considerations. Xenobiotica; the fate of foreign compounds in biological systems. 2022-08-30. PMID:36039395. |
many peptide drugs such as insulin and glucagon-like peptide (glp-1) analogues are successfully administered subcutaneously (sc). |
2022-08-30 |
2023-08-14 |
Not clear |
| Harshit Sajal, Shashank M Patil, Ranjith Raj, Abdullah M Shbeer, Mohammed Ageel, Ramith Ram. Computer-Aided Screening of Phytoconstituents from Molecules (Basel, Switzerland). vol 27. issue 16. 2022-08-26. PMID:36014373. |
dpp4 targets and inactivates incretin hormones such as glucagon-like peptide-1 (glp-1) and gastric inhibitory polypeptide (gip) as physiological substrates, which are essential to regulate the amount of insulin that is secreted after eating. |
2022-08-26 |
2023-08-14 |
human |
| Hui Li, Aimin Yang, Shi Zhao, Elaine Yk Chow, Mohammad Javanbakht, Yinhui Li, Dandan Lin, Lijuan Xu, Deng Zang, Kai Wang, Li M. Continuous Subcutaneous Insulin Infusion (CSII) Combined with Oral Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomized, Controlled Trials. Pharmaceuticals (Basel, Switzerland). vol 15. issue 8. 2022-08-26. PMID:36015100. |
in terms of insulin dosage, an insulin pump (csii) combined with the glp-1 receptor agonist can significantly reduce insulin dosage. |
2022-08-26 |
2023-08-14 |
Not clear |
| André J Scheen, Régis P Radermecker, Nicolas Paquo. [Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes]. Revue medicale suisse. vol 18. issue 792. 2022-08-25. PMID:36004653. |
because of the complementarity of action of the two incretins, tirzepatide showed, in a dose-dependent manner (5, 10 and 15 mg), a better efficacy (greater reduction in hba1c and body weight) compared with placebo, basal insulin and two glp-1 analogues (dulaglutide and semaglutide) in the surpass program. |
2022-08-25 |
2023-08-14 |
Not clear |
| Shiying Shao, Xiaoling Zhang, Qinqin Xu, Ruping Pan, Yong Che. Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities. Pharmacology & therapeutics. 2022-08-24. PMID:36002078. |
currently, gastrointestinal hormone glucagon like peptide-1 (glp-1) has received significant attention in maintaining glucose homeostasis through mechanisms involving augmentation of insulin, inhibition of glucagon secretion and regulation of gut motility. |
2022-08-24 |
2023-08-14 |
Not clear |
| Peiqi Wang, Timothy A Hill, Justin Mitchell, Rebecca L Fitzsimmons, Weijun Xu, Zhixuan Loh, Jacky Y Suen, Junxian Lim, Abishek Iyer, David P Fairli. Modifying a Hydroxyl Patch in Glucagon-like Peptide 1 Produces Biased Agonists with Unique Signaling Profiles. Journal of medicinal chemistry. 2022-08-19. PMID:35984914. |
glucagon-like peptide-1 (glp-1) lowers blood glucose by inducing insulin but also has other poorly understood properties. |
2022-08-19 |
2023-08-14 |
Not clear |
| Chunhui Huang, Anandan Palani, Zhiqiang Yang, Qiaolin Deng, Vijay Reddy, Ravi P Nargund, Songnian Lin, Simona Altezza, Elisabetta Bianchi, Federica Orvieto, Paul Carringto. Discovery of Insulin/GLP-1/Glucagon Triagonists for the Treatment of Diabetes and Obesity. ACS medicinal chemistry letters. vol 13. issue 8. 2022-08-18. PMID:35978702. |
here we report the first example of a unimolecular triagonist to simultaneously target insulin, glp-1, and glucagon receptors, aiming for better glycemic control and superior weight loss. |
2022-08-18 |
2023-08-14 |
Not clear |
| Marlena M Holter, Mridusmita Saikia, Bethany P Cumming. Alpha-cell paracrine signaling in the regulation of beta-cell insulin secretion. Frontiers in endocrinology. vol 13. 2022-08-12. PMID:35957816. |
as an incretin hormone, glucagon-like peptide 1 (glp-1) lowers blood glucose levels by enhancing glucose-stimulated insulin secretion from pancreatic beta-cells. |
2022-08-12 |
2023-08-14 |
Not clear |
| Florencio Zaragoz. Non-Covalent Albumin Ligands in FDA-Approved Therapeutic Peptides and Proteins. Journal of medicinal chemistry. 2022-08-12. PMID:35961011. |
acylation with fatty acids or fatty α,ω-dicarboxylic acids has been used successfully to prepare long-acting analogs of insulin, glp-1, and other peptides but not of larger proteins. |
2022-08-12 |
2023-08-14 |
human |
| Thorbjörn Åkerström, Malene N Stolpe, Renate Widmer, Thomas F Dejgaard, Jens M Højberg, Kirsten Møller, Jakob S Hansen, Beckey Trinh, Jens J Holst, Carsten Thomsen, Bente K Pedersen, Helga Ellingsgaar. Endurance Training Improves GLP-1 Sensitivity and Glucose Tolerance in Overweight Women. Journal of the Endocrine Society. vol 6. issue 9. 2022-08-08. PMID:35935071. |
the stimulatory effect of glucagon-like peptide 1 (glp-1) on insulin secretion is also impaired in obese, inactive individuals. |
2022-08-08 |
2023-08-14 |
Not clear |
| Christophe De Block, Clifford Bailey, Carol Wysham, Andrea Hemmingway, Sheryl Elaine Allen, Jennifer Pelesho. Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective. Diabetes, obesity & metabolism. 2022-08-05. PMID:35929488. |
in suprass-2, these reductions were greater than with the glp-1 receptor agonist semaglutide 1 mg. tirzepatide was well tolerated, with a low risk of hypoglycaemia when used without insulin or insulin secretagogues and showed a generally similar safety profile to the glp-1 receptor agonist class. |
2022-08-05 |
2023-08-14 |
Not clear |
| Hongle Yan, Chunyi Huang, Xuejun Shen, Jufang Li, Shuyi Zhou, Weiping L. GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis. Frontiers in endocrinology. vol 13. 2022-08-01. PMID:35909522. |
glp-1 ras and sglt-2 inhibitors for insulin resistance in nonalcoholic fatty liver disease: systematic review and network meta-analysis. |
2022-08-01 |
2023-08-14 |
Not clear |
| Hongle Yan, Chunyi Huang, Xuejun Shen, Jufang Li, Shuyi Zhou, Weiping L. GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis. Frontiers in endocrinology. vol 13. 2022-08-01. PMID:35909522. |
glucagon-like peptide-1 receptor agonists (glp-1 ras) and sodium-glucose cotransporter-2 (sglt-2) inhibitors reduce glycaemia and weight and improve insulin resistance (ir) |
2022-08-01 |
2023-08-14 |
Not clear |
| Bruno Vergè. Intestinal lipid absorption and transport in type 2 diabetes. Diabetologia. 2022-07-30. PMID:35908083. |
in individuals with type 2 diabetes, insulin resistance and possibly reduced glp-1 secretion are involved in the pathophysiology of postprandial hyperlipidaemia. |
2022-07-30 |
2023-08-14 |
human |
| Andrej Janez, Emir Muzurovic, Anca Pantea Stoian, Martin Haluzik, Cristian Guja, Leszek Czupryniak, Lea Duvnjak, Nebojsa Lalic, Tsvetalina Tankova, Pawel Bogdanski, Nikolaos Papanas, Josè Silva Nunes, Peter Kempler, Zlatko Fras, Manfredi Rizz. Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group. International journal of cardiology. 2022-07-29. PMID:35905827. |
glucagon-like peptide-1 (glp-1) receptor agonists mimic the action of the endogenous glp-1 incretin hormone, improving glycaemic control in type 2 diabetes mellitus (t2dm) by increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. |
2022-07-29 |
2023-08-14 |
Not clear |
| Darko Stefanovski, Mary A Robinson, Andrew Van Ep. Effect of a GLP-1 mimetic on the insulin response to oral sugar testing in horses. BMC veterinary research. vol 18. issue 1. 2022-07-29. PMID:35906619. |
effect of a glp-1 mimetic on the insulin response to oral sugar testing in horses. |
2022-07-29 |
2023-08-14 |
Not clear |
| Zaizhong Ni, Yanan Wang, Cong Shi, Xinping Zhang, Hao Gong, Yuwei Don. Islet MC4R Regulates PC1/3 to Improve Insulin Secretion in T2DM Mice via the cAMP and β-arrestin-1 Pathways. Applied biochemistry and biotechnology. 2022-07-28. PMID:35900711. |
it has been demonstrated that in the pancreas, it is expressed in islet α and β cells, wherein it is significantly correlated with insulin and glucagon-like peptide-1 (glp-1) secretion. |
2022-07-28 |
2023-08-14 |
mouse |
| Zaizhong Ni, Yanan Wang, Cong Shi, Xinping Zhang, Hao Gong, Yuwei Don. Islet MC4R Regulates PC1/3 to Improve Insulin Secretion in T2DM Mice via the cAMP and β-arrestin-1 Pathways. Applied biochemistry and biotechnology. 2022-07-28. PMID:35900711. |
therefore, in this study, our aim was to clarify the signaling and target genes involved in the regulation of insulin and glp-1 secretion by islet mc4r. |
2022-07-28 |
2023-08-14 |
mouse |
| Zaizhong Ni, Yanan Wang, Cong Shi, Xinping Zhang, Hao Gong, Yuwei Don. Islet MC4R Regulates PC1/3 to Improve Insulin Secretion in T2DM Mice via the cAMP and β-arrestin-1 Pathways. Applied biochemistry and biotechnology. 2022-07-28. PMID:35900711. |
the results obtained showed that in islet cells, the expression of prohormone convertase 1/3 (pc1/3), which is correlated with islet glp-1 and insulin secretion, increased significantly under the action of the mc4r agonist, ndp-α-msh, but decreased under the action of the mc4r antagonist, agrp. |
2022-07-28 |
2023-08-14 |
mouse |
| Zaizhong Ni, Yanan Wang, Cong Shi, Xinping Zhang, Hao Gong, Yuwei Don. Islet MC4R Regulates PC1/3 to Improve Insulin Secretion in T2DM Mice via the cAMP and β-arrestin-1 Pathways. Applied biochemistry and biotechnology. 2022-07-28. PMID:35900711. |
these findings suggest that islet mc4r possibly affects pc1/3 expression via the camp and β-arrestin-1 pathways to regulate glp-1 and insulin secretion. |
2022-07-28 |
2023-08-14 |
mouse |